ReHeart (Human (Allogeneic) iPS Cell-derived Cardiomyocyte Patches) / Cuorips - LARVOL DELTA

Japan panel approves world’s first iPS cell-based therapies (Nikkei) - "The Ministry of Health, Labor and Welfare's committee on regenerative medicine products and biotechnologies approved heart muscle sheets derived from human iPS cells developed by Cuorips, a University of Osaka-born startup. The committee also approved Amchepry, a candidate treatment for Parkinson's disease developed by Japanese drugmaker Sumitomo Pharma....The trials observed symptom improvement in four of six Parkinson's patients, and in all eight heart failure patients."

Japan approval • Parkinson's Disease